UroGen Pharma to Present at Upcoming Conferences

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) announced its participation in two virtual healthcare conferences in January. The company will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 9:45 a.m. ET, and its presentation will be available on-demand at the HC Wainwright BioConnect Conference starting on January 10 at 7:00 a.m. ET. Webcasts for both events will be accessible via the investors section of UroGen’s website, with replays available for 30 days.

UroGen focuses on innovative treatments for urothelial and specialty cancers.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in January:

40^th Annual J.P. Morgan Healthcare Conference

• Thursday, January 13 at 9:45 a.m. ET

HC Wainwright BioConnect Conference

• Presentation available on-demand beginning Monday, January 10 at 7:00 a.m. ET

Webcasts of both the J.P. Morgan and HC Wainwright presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^TM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005366/en/

INVESTOR CONTACT:

Lee Roth

lroth@burnsmc.com

212-213-0006



MEDIA CONTACT:

Cindy Romano

UroGen Corporate Communications

cindy.romano@urogen.com

908.963.7827

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma present at the J.P. Morgan Healthcare Conference?

UroGen Pharma will present at the J.P. Morgan Healthcare Conference on January 13 at 9:45 a.m. ET.

How can I access UroGen's presentations at the HC Wainwright BioConnect Conference?

UroGen's presentations at the HC Wainwright BioConnect Conference will be available on-demand starting January 10 at 7:00 a.m. ET.

Where can I find the webcasts of UroGen's conference presentations?

Webcasts of UroGen's conference presentations will be available in the investors section of their website.

How long will the webcasts of UroGen's presentations be available?

The webcasts of UroGen's presentations will be available for approximately 30 days.

What is the focus of UroGen Pharma's research and development?

UroGen Pharma focuses on developing novel solutions for treating urothelial and specialty cancers.